- Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)2023 | First Faculty of Medicine
- Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence2014 | First Faculty of Medicine
- Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial2018 | First Faculty of Medicine
- Evolocumab for the treatment of familial hypercholesterolemia2017 | Faculty of Medicine in Hradec Králové
- The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?2018 | Faculty of Medicine in Hradec Králové
- In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events2020 | Publication without faculty affiliation
- Dynamics of blood count after rheohemapheresis in age-related macular degeneration: Possible association with clinical changes2014 | Faculty of Medicine in Hradec Králové
- Clinical Management of High and Very High Risk Patients with Hyperlipidaemia in Central and Eastern Europe: An Observational Study2019 | First Faculty of Medicine
- Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study2021 | First Faculty of Medicine
- Role of lomitapide in treatment of severe familial hypercholesterolaemia2020 | Faculty of Medicine in Hradec Králové
- Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial2014 | First Faculty of Medicine
- Residual vascular risk in diabetes - Will the SPPARM alpha concept hold the key?Publication without faculty affiliation
- Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia +12007 | Faculty of Medicine in Hradec Králové
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome2020 | Publication without faculty affiliation
- Blood pressure control and risk profile in poststroke survivors: a comparison with the general population2015 | Faculty of Physical Education and Sport, First Faculty of Medicine, Faculty of Medicine in Pilsen
- Combined hypolipidemic therapy using statins and fibrates reducing the cardiovascular risk in the patients with atherogenic dyslipidemia2010 | Faculty of Medicine in Hradec Králové
- Komentář k článku: Léčba hypercholesterolemie v primární prevenci2019 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Metabolic syndrome - diagnostics and therapy2010 | Faculty of Medicine in Hradec Králové, Faculty of Physical Education and Sport, First Faculty of Medicine, Faculty of Medicine in Pilsen
- PCSK9 inhibitor evolocumab in the FOURIER outcomes trial2017 | First Faculty of Medicine
- Evolocumab - novel options in the treatment of hyperlipidemia2016 | Faculty of Medicine in Hradec Králové
- Atherosclerotic cardiovascular diseases and clinical signifikance of treatment with inclisiran2021 | Faculty of Medicine in Hradec Králové
- Nedostatečná korekce hodnot LDL cholesterolu u nemocných s periferní aterosklerózou: jak zlepšit tento stav?2022 | First Faculty of Medicine, Third Faculty of Medicine
- Is Drinking of Coffee and Using Of Cardamom in the Kitchen Beneficial for our Health?2013 | Faculty of Science
- Anotation of interesting articles from foreign literature2018 | First Faculty of Medicine
- The association between lipid parameters and obesity in university students2016 | Faculty of Medicine in Pilsen
- What is the role of nutriceuticals in dyslipidemia management? Armolipid Plus +12017 | Faculty of Medicine in Pilsen
- Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry2019 | First Faculty of Medicine
- Combined hypolipidemic treatment in patients with high cardiovascular (CV) risk2009 | Faculty of Medicine in Hradec Králové